Ray Dalio's ARWR Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 95,552 shares of Arrowhead Pharmaceuticals, Inc. (ARWR) worth $5.99 M, representing 0.03% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in ARWR, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 35,586 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Arrowhead Pharmaceuticals (ARWR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arrowhead Pharmaceuticals (ARWR) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +35,586 | Add 59.34% | 95,552 | $62.70 |
| Q4 2025 | +59,966 | New Buy | 59,966 | $66.39 |
Ray Dalio's Arrowhead Pharmaceuticals Investment FAQs
Ray Dalio first purchased Arrowhead Pharmaceuticals, Inc. (ARWR) in Q4 2025, acquiring 59,966 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Arrowhead Pharmaceuticals, Inc. (ARWR) for 2 quarters since Q4 2025.
Ray Dalio's largest addition to Arrowhead Pharmaceuticals, Inc. (ARWR) was in Q4 2025, adding 59,966 shares worth $3.98 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 95,552 shares of Arrowhead Pharmaceuticals, Inc. (ARWR), valued at approximately $5.99 M.
As of the Q1 2026 filing, Arrowhead Pharmaceuticals, Inc. (ARWR) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Arrowhead Pharmaceuticals, Inc. (ARWR) was 95,552 shares, as reported at the end of Q1 2026.